Literature DB >> 20498239

Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome.

Sylvie Nathanson1, Thérésa Kwon, Monique Elmaleh, Marina Charbit, Emma Allain Launay, Jérôme Harambat, Muriel Brun, Bruno Ranchin, Flavio Bandin, Sylvie Cloarec, Guylhene Bourdat-Michel, Christine Piètrement, Gérard Champion, Tim Ulinski, Georges Deschênes.   

Abstract

BACKGROUND AND OBJECTIVES: Neurologic involvement is the most threatening complication of diarrhea-associated hemolytic uremic syndrome (D+HUS). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We report a retrospective multicenter series of 52 patients with severe initial neurologic involvement that occurred in the course of D+HUS.
RESULTS: Verotoxigenic Escherichia coli infection was documented in 24. All except two patients had acute renal failure that required peritoneal dialysis, hemodialysis, or both techniques. A first group of eight patients remained with normal consciousness; five of them had protracted seizures. A second group of 23 patients had stuporous coma; five of these had protracted severe seizures, and 18 had a neurologic defect including pyramidal syndrome, hemiplegia or hemiparesia, and extrapyramidal syndrome. A third group of 21 patients had severe coma. Plasma exchanges were undertaken in 25 patients, 11 of whom were treated within 24 hours after the first neurologic sign; four died, two survived with severe sequelae, and five were alive without neurologic defect. Magnetic resonance imaging (MRI) for 29 patients showed that (1) every structure of the central nervous system was susceptible to involvement; (2) no correlation seemed to exist between special profile of localization on early MRI and the final prognosis; and (3) MRI did not exhibit any focal lesions in three patients. The overall prognosis of the series was marked by the death of nine patients and severe sequelae in 13.
CONCLUSIONS: Neurologic involvement is associated with a severe renal disease but does not lead systematically to death or severe disability.

Entities:  

Mesh:

Year:  2010        PMID: 20498239      PMCID: PMC2893076          DOI: 10.2215/CJN.08921209

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  27 in total

1.  Neurological complications of hemolytic-uremic syndrome.

Authors:  J S Hahn; P L Havens; J J Higgins; P P O'Rourke; J A Estroff; R Strand
Journal:  J Child Neurol       Date:  1989-04       Impact factor: 1.987

2.  Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology.

Authors:  C Loirat; E Sonsino; N Hinglais; J P Jais; P Landais; J Fermanian
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

3.  Coma scales in pediatric practice.

Authors:  J Y Yager; B Johnston; S S Seshia
Journal:  Am J Dis Child       Date:  1990-10

4.  Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells.

Authors:  Patricia B Eisenhauer; Mary S Jacewicz; Kelly J Conn; Omanand Koul; John M Wells; Richard E Fine; David S Newburg
Journal:  Microb Pathog       Date:  2004-04       Impact factor: 3.738

5.  Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome.

Authors:  N Cimolai; B J Morrison; J E Carter
Journal:  Pediatrics       Date:  1992-10       Impact factor: 7.124

6.  Neurological involvement in hemolytic-uremic syndrome.

Authors:  K J Sheth; H M Swick; N Haworth
Journal:  Ann Neurol       Date:  1986-01       Impact factor: 10.422

7.  CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings.

Authors:  Marc Steinborn; Steffen Leiz; Klaus Rüdisser; Martin Griebel; Thomas Harder; Helmut Hahn
Journal:  Pediatr Radiol       Date:  2004-07-29

8.  CNS manifestations of the hemolytic-uremic syndrome. Relationship to metabolic alterations and prognosis.

Authors:  J F Bale; C Brasher; R L Siegler
Journal:  Am J Dis Child       Date:  1980-09

9.  Reversible MR findings of hemolytic uremic syndrome with mild encephalopathy.

Authors:  H Ogura; M Takaoka; M Kishi; M Kimoto; T Shimazu; T Yoshioka; H Sugimoto
Journal:  AJNR Am J Neuroradiol       Date:  1998 Jun-Jul       Impact factor: 3.825

Review 10.  Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome.

Authors:  E G Gallo; C A Gianantonio
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

View more
  62 in total

1.  Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.

Authors:  Michelle Schoettler; Christine Duncan; Leslie Lehmann
Journal:  Pediatr Transplant       Date:  2019-03-03

2.  Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience.

Authors:  Takeshi Ninchoji; Kandai Nozu; Keita Nakanishi; Tomoko Horinouchi; Junya Fujimura; Tomohiko Yamamura; Shogo Minamikawa; Shingo Ishimori; Koichi Nakanishi; Norishige Yoshikawa; Ichiro Morioka; Hiroshi Kaito; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2017-01-10       Impact factor: 2.801

3.  Blood urea nitrogen to serum creatinine ratio is an accurate predictor of outcome in diarrhea-associated hemolytic uremic syndrome, a preliminary study.

Authors:  Werner Keenswijk; Jill Vanmassenhove; Ann Raes; Evelyn Dhont; Johan Vande Walle
Journal:  Eur J Pediatr       Date:  2017-01-11       Impact factor: 3.183

Review 4.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

5.  Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome.

Authors:  Gianluigi Ardissino; Valeria Daccò; Sara Testa; Cristina Felice Civitillo; Francesca Tel; Ilaria Possenti; Mirco Belingheri; Pierangela Castorina; Nicolò Bolsa-Ghiringhelli; Silvana Tedeschi; Fabio Paglialonga; Stefania Salardi; Dario Consonni; Elena Zoia; Patrizia Salice; Giovanna Chidini
Journal:  Pediatr Nephrol       Date:  2014-08-23       Impact factor: 3.714

6.  C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Bataglia; Ismael Toledo; Laura Beaudoin; Caupolican Alvarado
Journal:  Pediatr Nephrol       Date:  2019-09-02       Impact factor: 3.714

7.  Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo; Caupolican Alvarado; Raquel Eva Wainsztein
Journal:  Pediatr Nephrol       Date:  2013-02-06       Impact factor: 3.714

Review 8.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

9.  The ether lipid precursor hexadecylglycerol protects against Shiga toxins.

Authors:  Jonas Bergan; Tore Skotland; Anne Berit Dyve Lingelem; Roger Simm; Bjørn Spilsberg; Toril Lindbäck; Tuulia Sylvänne; Helena Simolin; Kim Ekroos; Kirsten Sandvig
Journal:  Cell Mol Life Sci       Date:  2014-04-18       Impact factor: 9.261

10.  Diarrhea-associated hemolytic uremic syndrome with severe neurological manifestations treated with IgG depletion through immunoadsorption.

Authors:  Benjamin Flam; Peter Sackey; Andreas Berge; Anne C Zachau; Bo Brink; Sigrid Lundberg
Journal:  J Nephrol       Date:  2016-03-19       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.